(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 3, 2011, Pages 659-663

  Maes, Michael ^a   Leonard, Brian ^b   Fernandez, Alberto ^c   Kubera, Marta ^d   Nowak, Gabriel ^d   Veerhuis, Rob ^e   Gardner, Ann ^f   Ruckoanich, Piaynuj ^a   Geffard, Michel ^g   Altamura, Carlo ^h   Galecki, Piotr ⁱ   Berk, Michael ^j,k  

^a Piyavate Hospital   (Thailand)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c Palau Pharma   (Spain)

^d INSTITUTE OF PHARMACOLOGY   (Poland)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f KAROLINSKA INSTITUTE   (Sweden)

^g In Human Pathology and Therapy   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ MEDICAL UNIVERSITY OF LODZ   (Poland)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CURCUMIN; ENDOTHERAPIA; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; JANUS KINASE 3 INHIBITOR; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NERVE CELL ADHESION MOLECULE; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; PROTEIN KINASE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; STAT PROTEIN; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; DEPRESSION; DRUG DISCOVERY; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEUROIMMUNOMODULATION; PROTEIN KINASE INHIBITORS;

EID: 79954592668     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.02.019     Document Type: Editorial

References (87)

1. Aaronson D.S., Horvath C.M. A road map for those who don't know JAK-STAT. Science 2002, 296(5573):1653-1655.
2. Bartholomä P., Erlandsson N., Kaufmann K., Rössler O.G., Baumann B., Wirth T., et al. Neuronal cell death induced by antidepressants: lack of correlation with Egr-1, NF-kappa B and extracellular signal-regulated protein kinase activation. Biochem Pharmacol 2002, 63(8):1507-1516.
3. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64(6):468-475.
4. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
5. Bjarnason I., Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009, 44(Suppl 19):23-29.
6. Borders A.S., de Almeida L., Van Eldik L.J., Watterson D.M. The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target. BMC Neurosci 2008, 9(Suppl 2):S12.
7. Brasier A.R. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006, 6(2):111-130.
8. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., et al. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006, 21(4):219-225.
9. Bumrungpert A., Kalpravidh R.W., Chuang C.C., Overman A., Martinez K., Kennedy A., et al. Xanthones from mangosteen inhibit inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media. J Nutr 2010, 140(4):842-847.
10. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010, 185(2):1230-1237.
11. Connor T.J., Kelliher P., Shen Y., Harkin A., Kelly J.P., Leonard B.E. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav 2000, 65(4):591-597.
12. Diamond M., Kelly J.P., Connor T.J. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol 2006, 16(7):481-490.
13. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001, 77(3):916-928.
14. Feng P., Guan Z., Yang X., Fang J. Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine. Brain Res 2003, 991(1-2):195-205.
15. Gardner A., Boles R.G. Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:730-743. (this issue).
16. Geffard M., de Bisschop L., Duleu S., Hassaine N., Mangas A., Coveñas R. Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discov Med 2010, 10(54):443-451.
17. Hoogendijk W.J., Lips P., Dik M.G., Deeg D.J., Beekman A.T., Penninx B.W. Depression is associated with decreased 25-hydroxy vitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008, 65(5):508-512.
18. Igaz P., Tóth S., Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res 2001, 50(9):435-441.
19. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005, 1754(1-2):253-262.
20. Kennedy S.H., Segal Z.V., Cohen N.L., Levitan R.D., Gemar M., Bagby R.M. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry 2003, 64(4):439-444.
21. Kiecolt-Glaser J.K., Preacher K.J., MacCallum R.C., Atkinson C., Malarkey W.B., Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003, 100(15):9090-9095.
22. Kirsch I. Antidepressants and the placebo response. Epidemiol Psichiatr Soc 2009, 18(4):318-322.
23. Kirsch I., Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials 2007, 28(4):348-351.
24. Klementiev B., Novikova T., Novitskaya V., Walmod P.S., Dmytriyeva O., Pakkenberg B., et al. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 2007, 145(1):209-224.
25. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011, 218(1):57-63.
26. Kubera M., Kenis G., Bosmans E., Scharpé S., Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 2000, 23(1):89-98.
27. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 2000, 96(3):255-266.
28. Kubera M., Lin A.H., Kenis G., Bosmans E., van Bockstaele D., Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001, 21(2):199-206.
29. Kubera M., Maes M., Kenis G., Kim Y.K., Lasoñ W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 2005, 134(3):251-258.
30. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):744-759. (this issue).
31. Kulkarni S., Dhir A., Akula K.K. Potentials of curcumin as an antidepressant. Sci World J 2009, 9:1233-1241.
32. Leonard B.E. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010, 6(3):205-212.
33. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993, 4(4):407-416.
34. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19(1):11-38.
35. Maes M. The immune pathophysiology of major depression. Depression: Neurobiological, Psychopathological and Therapeutic Advances 1997, 197-215. John Wiley. A. Honig, H. van Praag (Eds.).
36. Maes M. An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):784-794. (this issue).
37. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):664-675.
38. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990-1991, 24(3):115-120.
39. Maes M., Bosmans E., Suy E., Vandervorst C., DeJonckheere C., Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991, 84(4):379-386.
40. Maes M., Bosmans E., Meltzer H.Y., Scharpé S., Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression. Am J Psychiatry 1993, 150(8):1189-1193.
41. Maes M., Meltzer H.Y., Scharpé S., Bosmans E., Suy E., De Meester I., et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993, 49(2):151-165.
42. Maes M., Scharpé S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994, 54(2):143-160.
43. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995, 20(2):111-116.
44. Maes M., Song C., Lin A., De Jongh R., Van Gastel A., Kenis G., et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998, 10(4):313-318.
45. Maes M., Song C., Lin A.H., Bonaccorso S., Kenis G., De Jongh R., et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999, 20(4):370-379.
46. Maes M., Kubera M., Leunis J.C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008, 29(1):117-124.
47. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24(1):27-53.
48. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):676-692. (this issue).
49. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):702-721. (this issue).
50. Maes M., Ruckoanich P., Chang Y.S., Mahanonda N., Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):769-783. (this issue).
51. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006, 21(4):227-231.
52. Mingmalairak S., Tohda M., Murakami Y., Matsumoto K. Possible involvement of signal transducers and activators of transcription 3 system on depression in the model mice brain. Biol Pharm Bull 2010, 33(4):636-640.
53. Moncrieff J., Cohen D. Do antidepressants cure or create abnormal brain states PLoS Med 2006, 3(7):e240.
54. Moncrieff J., Wessely S., Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004, (1):CD003012.
55. Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11(7):680-684.
56. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl):S121-S131.
57. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009, 12(5):687-699.
58. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010, 79(5):323-325.
59. Patten S.B. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004, 2(1):9.
60. Periyasamy S., Sánchez E.R. Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression. Int J Biochem Cell Biol 2002, 34(12):1571-1585.
61. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J Cell Sci 2004, 117(Pt 8):1281-1283.
62. Sandi C., Bisaz R. A model for the involvement of neural cell adhesion molecules in stress-related mood disorders. Neuroendocrinology 2007, 85(3):158-176.
63. Schindler J.F., Monahan J.B., Smith W.G. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007, 86(9):800-811.
64. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83(4):754-759.
65. Simon A.R., Rai U., Fanburg B.L., Cochran B.H. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 1998, 275(6 Pt 1):C1640-C1652.
66. Smith R.S. The macrophage theory of depression. Med Hypotheses 1991, 35(4):298-306.
67. Song C., Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):760-768.
68. Steptoe A., Willemsen G., Owen N., Flower L., Mohamed-Ali V. Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. Clin Sci Lond 2001, 101(2):185-192.
69. Strnad J., Burke J.R. IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol Sci 2007, 28(3):142-148.
70. Szewczyk B., Kubera M., Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):693-701.
71. Tewtrakul S., Wattanapiromsakul C., Mahabusarakam W. Effects of compounds from Garcinia mangostana on inflammatory mediators in RAW264.7 macrophage cells. J Ethnopharmacol 2009, 121(3):379-382.
72. Tsao C.W., Lin Y.S., Cheng J.T., Lin C.F., Wu H.T., Wu S.R., et al. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 2008, 22(7):753-760.
73. Tuma T. Outcome of hospital treated depression at 4.5years. An elderly and a younger cohort compared. Br J Psychiatry 2000, 176:224-228.
74. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358(3):252-260.
75. Walker J.G., Smith M.D. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005, 32(9):1650-1653.
76. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16(3):239-249.
77. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009, 10(5):491-504.
78. Xia Z., DePierre J.W., Nässberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 1996, 34(1):27-37.
79. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 2005, 82(1):200-206.
80. Xu Y., Ku B., Cui L., Li X., Barish P.A., Foster T.C., et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007, 1162:9-18.
81. Yirmiya R. Behavioral and psychological effects of immune activation: implications for 'depression due to a general medical condition'. Curr Opin Psychiatry 1997, 10:470-476.
82. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001, 24(5):531-544.
83. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001, 276(34):31674-31683.
84. Zhu C.B., Carneiro A.M., Dostmann W.R., Hewlett W.A., Blakely R.D. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 2005, 280(16):15649-15658.
85. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31(10):2121-2131.
86. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35(13):2510-2520.
87. Zunszain P.A., Anacker C., Cattaneo A., Carvalho L.A., Pariante C.M. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):722-729.